A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

Overview of attention for article published in Journal of Hematology & Oncology, September 2018

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 28 Dimensions

Readers on

mendeley: 28 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 952 followers.

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis. https://t.co/W0MYAGjOzF https://t.co/lXTAFSq8IZ

26 Sep 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.